[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shenzhen People's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":166},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,69,91,116,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100632312","oral-lactobacillus-reuteri-for-skin-barrier-dysfunction-in-obesity-100632312",false,"NCT07512050","Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity","A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Oral Lactobacillus Reuteri in Treating Skin Barrier Function Impairment Caused by Obesity.","Inclusion Criteria:\n\n* 1\\. Meets 2020 WHO BMI classification:\n* a. Normal weight (18.5-24.9 kg\u002Fm²)\n* b. Overweight (25-29.9 kg\u002Fm²)\n* c. Obesity (≥30 kg\u002Fm²)\n* 2\\. Presence of skin barrier impairment (e.g., dryness, erythema, desquamation, or itching)\n* 3\\. Age 18-40 years\n* 4\\. Generally good health (no active systemic diseases)\n* 5\\. Able and willing to provide written informed consent\n* 6\\. No use of oral\u002Ftopical medications or probiotics within 6 months prior\n* 7\\. No active skin disease or traumatic skin lesions\n\nExclusion Criteria:\n\n* 1\\. Known allergy or hypersensitivity to probiotics, placebo, or investigational product\n* 2\\. Active skin disease (e.g., psoriasis, eczema, infection) requiring treatment\n* 3\\. Severe medical conditions:\n* a. Cardiopulmonary disease (NYHA class III\u002FIV)\n* b. Uncontrolled diabetes (HbA1c \\>9%)\n* c. Autoimmune disorders\n* 4\\. Pregnant or breastfeeding women\n* 5\\. Any condition that may interfere with protocol compliance (per investigator judgement), including:\n* a. Inability to understand study procedures\n* b. History of poor clinical trial adherence\n* 6\\. Concurrent participation in other interventional trials",true,"ALL","18 Years","40 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial aims to evaluate the safety and efficacy of oral Lactobacillus reuteri supplementation for treating obesity-induced skin barrier impairment in individuals aged 18-40 with a BMI ≥30. The study focuses on the following questions:\n\nCan oral Lactobacillus reuteri supplementation reduce skin barrier damage (measured by transepidermal water loss\u002FTEWL) in obese participants? Does modulation of gut microbiota with Lactobacillus reuteri impact skin barrier function and systemic inflammation?\n\nResearchers will compare outcomes across two groups:\n\nIntervention Group (Obese): Oral Lactobacillus reuteri capsules. Placebo Control Group (Obese): Oral inactive (heat-killed) Lactobacillus reuteri.\n\nParticipant Procedures:\n\nTake daily oral capsules (Lactobacillus reuteri or inactive strain) for 4 weeks.\n\nUndergo non-invasive skin testing (TEWL measurements) at baseline and study completion.\n\nProvide stool and samples for analyses. Complete weekly check-ins to report adverse effects (e.g., gastrointestinal discomfort, skin irritation).",[28,29],"Skin Barrier to Water Loss","Microbial Colonization","NOT_YET_RECRUITING","2026-03-31",{"date":33,"type":34},"2026-04-06","ACTUAL",{"date":36,"type":22},"2026-04-10",{"date":38,"type":22},"2026-07-30",{"name":40,"class":41},"Shenzhen People's Hospital","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100621430","phase-2-topical-application-of-lactobacillus-reuteri-for-androgenetic-alopecia-100621430","NCT07370519","Topical Application of Lactobacillus Reuteri for Androgenetic Alopecia","Safety and Efficacy of Lactobacillus Reuteri for Androgenetic Alopecia: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Patients meeting AGA diagnostic criteria (confirmed by medical history, clinical presentation, and trichoscopy) classified as Norwood-Hamilton stage II-IV or Ludwig grade I-III;\n2. Provision of informed consent and voluntary participation;\n3. Aged 18-60 years with generally good health status;\n4. No use of any hair loss medications within the past six months;\n5. Absence of alopecia areata, local infections, or neuromuscular disorders.\n\nExclusion Criteria:\n\n1. AGA progression \\>5 years;\n2. Active skin disease (e.g., psoriasis flare) or uncontrolled diabetes\u002FCVD;\n3. Investigator-assessed protocol non-feasibility.","60 Years",{"count":51,"type":22},388,[53],"PHASE2","This is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate whether topical application of Lactobacillus reuteri can safely and effectively treat androgenetic alopecia. The study is based on the concept that balancing the scalp's microbial community may support hair follicle function. Participants will be randomly assigned to one of four groups receiving either active probiotic solution, inactivated probiotic solution (control for non-viable bacterial effects), a saline placebo, or the standard treatment 5% minoxidil solution for 12 months. Neither participants nor assessing clinicians will know the assigned treatment. The main goal is to measure improvement in hair count per square centimeter after one year. Additional measures include changes in hair thickness and quality. This research seeks to provide high-quality scientific evidence on a new microbiome-targeting approach, offering future patients and healthcare providers insights into a potential alternative or complementary treatment strategy for hair loss.",[56],"Androgenetic Alopecia (AGA)",[58,59],"Androgenetic Alopecia","Lactobacillus reuteri","RECRUITING",{"date":62,"type":34},"2026-04-01",{"date":64,"type":34},"2026-01-25",{"date":66,"type":22},"2027-06",{"name":40,"class":41},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":68},"100621100","phase-2-topical-application-of-engineered-lactobacillus-reuteri-with-a-zinc-sulfate-tannic-acid-mpn-coating-for-acne-100621100","NCT07366229","Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne","Evaluating Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne: A Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Subjects must be diagnosed with acne (based on history, clinical manifestation, and dermatoscopy) and classified as Grade I to III per the International Improved Grading System.\n2. Subjects must be willing and able to provide written informed consent.\n3. Subjects must be 18 to 33 years of age and in generally good health.\n4. Subjects must have more than 9 inflammatory lesions.\n\nExclusion Criteria:\n\n1. Have used antibiotics within 1 month before the study start.\n2. Have used systemic retinoid therapy within 3 months before the study start.\n3. Have undergone any other acne treatment within 1 month before the study start.\n4. Have any other condition that the investigator considers would make participation unsuitable (e.g., deemed unreliable, non-compliant, or unable to comprehend the study assessments).","33 Years",{"count":78,"type":22},196,[53],"A growing body of evidence suggests that the development and progression of acne are closely linked to an imbalance in the skin's microbial community. Compared to healthy skin, the composition and function of the microbiota in acne lesions are significantly altered. This microbial imbalance is believed to drive the formation and recurrence of acne through mechanisms such as triggering abnormal inflammatory responses and compromising the skin barrier.\n\nAn in-depth exploration of the interaction between acne and the skin microbiome not only offers new perspectives for understanding the root causes of the disease but also lays the groundwork for developing novel treatment strategies aimed at modulating the microbiota. Therefore, identifying innovative approaches that integrate acne treatment with the regulation of microbial balance holds significant clinical and social value.\n\nAlthough existing acne treatments have made progress, research focusing on interventions that regulate the local skin microecology through probiotics remains relatively limited. This study aims to explore a new strategy based on skin microecological modulation. Investigators are using a common probiotic-Lactobacillus reuteri-and applying an engineering modification with a special coating formed by zinc sulfate and tannic acid (MPN coating). This modification is intended to enhance the bacterium's survival and colonization on the skin, thereby more effectively regulating the local microbiota and reducing inflammation.\n\nThis study is a rigorous scientific clinical trial designed as randomized, double-blind, and controlled. Eligible participants will be randomly assigned to one of four groups, receiving either the engineered Lactobacillus reuteri cream, the plain Lactobacillus reuteri cream, a simple moisturizing cream (placebo), or an already-marketed effective cream (tretinoin cream). The treatment will last for 2 weeks, followed by an 8-week observation period. Efficacy and safety will be evaluated through professional assessments.\n\nOur goal is to scientifically evaluate the safety and efficacy of this new therapy, hoping to provide a potential new treatment option for individuals with acne and explore new pathways for improving skin health.",[82],"Acne",[84,59],"acne",{"date":33,"type":34},{"date":87,"type":34},"2025-12-30",{"date":89,"type":22},"2026-06-30",{"name":40,"class":41},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":98,"maxAge":49,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":115,"locationsCount":68},"100607872","phase-2-safety-and-efficacy-of-lactobacillus-plantarum-for-psoriasis-a-randomized-double-blind-placebo-controlled-trial-100607872","NCT07194200","Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial","Evaluating the Safety and Efficacy of Lactobacillus Plantarum in Treating Psoriasis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Reference to Psoriasis Area and Severity Index (PASI) score \\\u003C 10 Patients have been informed of the study details, voluntarily participate, and have signed the informed consent form; Aged 18-60 years with good general health status; No use of any medications within 6 months; No various inflammatory or immune skin diseases, no local infections, and no neuromuscular diseases.\n\nExclusion Criteria:\n\n* Patients with other types of psoriasis or severe psoriasis; Those in the active phase of skin diseases or with other serious diseases; Other situations deemed unsuitable for enrollment by the researchers, such as subjects who are untrustworthy, unable to accept or understand the study assessments.","16 Years",{"count":100,"type":22},184,[53],"A growing body of evidence indicates that the pathogenesis of psoriasis may be closely linked to skin microbiome dysbiosis. Compared with healthy individuals, the composition and function of the skin microbiota in psoriasis patients exhibit significant alterations5,6. This microbial imbalance is thought to contribute to the initiation and progression of the disease through mechanisms such as triggering abnormal immune responses, exacerbating inflammatory processes, and impairing the skin barrier.\n\nIn-depth exploration of the interplay between psoriasis and the microbiome not only offers new perspectives for elucidating the disease's pathogenesis but also lays the groundwork for developing innovative microbiota-targeted diagnostic and therapeutic strategies. Thus, identifying novel therapeutic approaches that bridge psoriasis treatment and microbial regulation holds substantial clinical and social value.\n\nWhile existing treatments for psoriasis have made some progress, research specifically focusing on the microbiota-psoriasis relationship remains relatively limited. Investigating the intrinsic connections between microecological balance and psoriasis management, and developing practical improvement strategies, is therefore of crucial practical significance for enhancing skin health and improving quality of life. This study aims to address this research gap and provide a new therapeutic option for individuals with psoriasis.",[104,105],"Psoriasis","Lactobacillus Plantarum",[107,108],"psoriasis","Lactobacillus plantarum","2025-12-22",{"date":111,"type":34},"2025-12-24",{"date":113,"type":34},"2025-12-15",{"date":89,"type":22},{"name":40,"class":41},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":124,"minAge":18,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":68},"100608595","phase-1-a-study-on-the-treatment-of-androgenetic-alopecia-in-young-men-with-umbilical-cord-mesenchymal-stem-cell-exosomes-100608595","NCT07203599","A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes","A Randomized Controlled Clinical Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes","MSCs treatment","Inclusion Criteria:\n\n* 1\\. Male patients aged 18-35 2. Clinically diagnosed with androgenic alopecia, Hamilton Norwood Scale III-V 3. Patients who voluntarily participate in clinical trials and sign informed consent forms\n\nExclusion Criteria:\n\n* 1\\. Known alcohol allergy 2. Patients with severe primary diseases of cardiovascular, cerebrovascular, liver, kidney, endocrine, or hematopoietic system 3. Patients with other scalp diseases or hair loss diseases 4. Patients with severe mental illness and cognitive impairment 5. Patients with poor nutritional status and low immune function 6. Within 1 year, those who have used systemic corticosteroids, immunosuppressants, cytotoxic drugs, and peripheral vasodilators 7. Within 6 months, those who have used systemic or local drugs to treat hair loss, such as finasteride, minoxidil, etc 8. Within 3 months, those who have received other clinical trial drugs 9. Family genetic history or other criteria considered unsuitable by researchers","MALE","35 Years",{"count":127,"type":22},59,[129,53],"PHASE1","This clinical trial aims to determine the efficacy of human umbilical cord mesenchymal stem cell exosomes (hUCMSC-sEV) in treating androgenic alopecia in young men. It will also investigate the safety of hUCMSC-sEV. The primary inquiry it seeks to address is:\n\n* Do hUCMSC-sEV demonstrate efficacy in the treatment of androgenic alopecia in young men?\n* Do hUCMSC-sEV safely used to treat androgenic alopecia in young men?\n\nThe clinical trial has two parts. The Phase I study is a dose-escalation trial. Researchers will determine the appropriate dosage of hUCMSC-sEV. The Phase II study is a randomized controlled trial. Researchers will evaluate hUCMSC-sEV against a placebo (minoxidil tincture) to determine the efficacy of hUCMSC-sEV in treating androgenic alopecia in young men.\n\nIn the phase I study, participants will be categorized into three dosage groups: A, B, and C. In Group A, one injection site will be allocated for each 1 cm² of hair loss area, delivering a dosage of 1.0×10\\^8 particles per site. In Group B, the dosage will be 1.0×10\\^9 particles per site. In Group C, the dosage will be 1.0×10\\^10 particles per site. Participants will attend the clinic at weeks 0, 2, 4, and 6 for treatment and assessments. Participants will also attend the clinic for follow-up examinations at weeks 8, 12, and 24.\n\nIn the phase II study, participants will be randomly allocated in a 1:1 ratio to two groups: the hUCMSC-sEV treatment group and the minoxidil treatment group. hUCMSC-sEV treatment group: the appropriate dose of hUCMSC-sEV for the phase II study was determined based on assessments of safety, tolerability, and preliminary efficacy from the phase I study. Participants will receive one injection site for each 1 cm² of hair loss area. Participants will attend the clinic for therapy and assessments at weeks 0, 2, 4, and 6. Minoxidil treatment group: participants will get 1 mL of minoxidil administered daily to the area of hair loss for 12 consecutive weeks. All patients will attend the clinic for follow-up examinations at weeks 8, 12, and 24.",[132],"Androgenic Alopecia",[134,135],"androgenic alopecia","human umbilical cord mesenchymal stem cell exosomes","2025-11-24",{"date":138,"type":34},"2025-12-02",{"date":140,"type":34},"2025-09-20",{"date":142,"type":22},"2026-11-01",{"name":40,"class":41},{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":68},"100481812","phase-3-s086-tablets-for-chronic-heart-failure-with-reduced-ejection-fraction-100481812","NCT05553886","S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction","A Randomized, Double-blind, Positive-drug Parallel Controlled, Multicenter Phase III Trial of the Efficacy and Safety of S086 Tablets in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)","Inclusion Criteria:\n\n1. Patients with chronic heart failure (NYHA grade ⅱ-ⅳ) with reduced ejection fraction (LVEF≤40%) and elevated BNP were diagnosed 1a.\n2. Patients received a stable dose of the underlying treatment for heart failure, defined as no change in dose for at least 4 weeks before screening 1b.\n3. Volunteer to participate in the trial and sign an informed consent form 1c.\n\nExclusion Criteria:\n\n1. Previous continuous administration of sacubitril valsartan sodium 150mg bid or more for more than 3 months 1a.\n2. Use of other study drugs or use of any study medical device within 1 day of the visit or within 30 days prior to the visit or within 5 half-lives of the drug, whichever is longer 1b.\n3. Known or suspected allergy to S086, sacubitril valsartan sodium, ARB, ACEI, or enkephin inhibitor (NEPI), and known or suspected contraindications to sacubitril valsartan sodium 1c.\n4. A previous history of intolerance to the recommended target dose of ACEI or ARB 1d.\n5. He had a history of angioedema 1e.\n6. Acute coronary syndrome occurred within 6 weeks before visit 1 1f.",{"count":152,"type":22},5,[154],"PHASE3","A randomized, double-blind, positive-drug parallel controlled, multicenter phase III trial of the efficacy and safety of S086 tablets in patients with chronic heart failure with reduced ejection fraction (HFrEF)",[157],"Chronic Heart Failure With Reduced Ejection Fraction","2022-10-31",{"date":160,"type":34},"2022-11-03",{"date":162,"type":34},"2021-12-21",{"date":164,"type":22},"2026-12-31",{"name":40,"class":41},""]